HARVARD BIOSCIENCE INC 8K

Harvard Bioscience furnished an investor presentation describing its strategic focus on translational science tools, recent debt refinancing and manufacturing consolidation, board and management changes, and updated 2026 financial outlook with supporting non-GAAP metrics.

Harvard Bioscience, Inc. furnished an investor presentation outlining its strategic transformation into a focused translational science tools company, highlighting recent actions including appointment of a new CEO effective July 2025 and a permanent CFO in March 2026, a $40 million debt refinancing that extends maturities to 2029 and adds a $7.5 million BroadOak convertible note investment, a phased consolidation and closure of its Holliston, MA manufacturing plant under “Project Viking” to shift production to Minneapolis and Europe with expected adjusted EBITDA improvements of $3 million in 2027 and $4 million annually thereafter, expansion of its board of directors with several new members including a BroadOak nominee, and updated 2026 financial guidance calling for modest revenue and adjusted EBITDA growth alongside high gross margins and an increasing share of recurring revenue. The presentation also provides detail on Harvard Bioscience’s global operations, product portfolio across preclinical systems and cellular/molecular technologies, non-GAAP reconciliations for 2Q26, and forward-looking statements regarding its market position, innovation pipeline, and operational efficiency initiatives.

Filing Facts

CIK

1123494

Ticker

-

Form

8K

Source Type

sec

Accession

0001171843-26-005406

Alert Tier

6